Foot and Mouth Antigen and Vaccine - Purchase, Storage and Emergency Production

Descriptions

Defra is exploring options for supply of antigen and vaccines to the UK foot and mouth disease (FMD) vaccine bank and is seeking to identify existing and potential suppliers who have FMD vaccines with robust evidence of quality, safety, and efficacy. We are keen to hear from suppliers who are in a position to supply suitable FMD vaccine products from early 2027 (including manufacturing lead times as necessary). Please provide the information detailed in the section below, but please note that Defra will not consider heterologous vaccine products. Those wishing to provide the information requested here should contact Melanie Swain (melanie.swain@defra.gov.uk), by the 8 September 2025. Defra reserves the right to follow up with suppliers on a 1:1 basis to further understand their capabilities with regard to this requirement. Defra is seeking this information to inform decisions around guarantees of supply to the UK market. Therefore the estimated total value shown below is only indicative at this stage.

Engagement

If your organisation is interested in this requirement, please provide the following information to the named contact above, via email: - The details of your organisation's FMD antigen and vaccine products. - Number and size of dose. - Data on safety, efficacy and period (onset and duration) of immunity in the target species. - Longevity/shelf life of vaccines and antigen. - The number of doses in the vaccination schedule. - Storage conditions and bottle sizes available. - The type of technology used to develop the vaccine production capacity. - Species that can be vaccinated and any data on the minimum age that animals can be vaccinated. - Whether the vaccine is produced to GMP standard or equivalent. - Whether the vaccine is manufactured and stored according to the WOAH Terrestrial Manual Chapter 3.1.8. - Whether the vaccine is currently authorised for use with a valid marketing authorisation and, if so, where is the vaccine authorised. - Whether the vaccine has been used elsewhere in the world. - Timelines for submitting applications for a marketing authorisation to VMD (if relevant). - The likely cost of the product. - Information on novel technologies and products and likely timeframe to market.